Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis
Autore:
Achiron, A; Miron, S; Lavie, V; Margalit, R; Biegon, A;
Indirizzi:
Chaim Sheba Med Ctr, Multiple Sclerosis Ctr, IL-52621 Tel Hashomer, Ramat Gan, Israel Chaim Sheba Med Ctr Tel Hashomer Ramat Gan Israel IL-52621 at Gan, Israel Kiryat Weizmann, Pharmos, Rehovot, Israel Kiryat Weizmann Rehovot Israel iryat Weizmann, Pharmos, Rehovot, Israel Weizmann Inst Sci, Dept Cell Biol, IL-76100 Rehovot, Israel Weizmann Inst Sci Rehovot Israel IL-76100 Biol, IL-76100 Rehovot, Israel
Titolo Testata:
JOURNAL OF NEUROIMMUNOLOGY
fascicolo: 1, volume: 102, anno: 2000,
pagine: 26 - 31
SICI:
0165-5728(20000103)102:1<26:D(EOEA>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
CLOSED-HEAD INJURY; NONCOMPETITIVE NMDA ANTAGONIST; NECROSIS-FACTOR-ALPHA; RAT; METHYLPREDNISOLONE; NEUROPROTECTANT; CANNABINOIDS; SUPPRESSION; ISCHEMIA; TERM;
Keywords:
EAE; multiple sclerosis; TNF-alpha inhibition; relapse; animal model;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Achiron, A Chaim Sheba Med Ctr, Multiple Sclerosis Ctr, IL-52621 Tel Hashomer, Ramat Gan, Israel Chaim Sheba Med Ctr Tel Hashomer Ramat Gan Israel IL-52621 ael
Citazione:
A. Achiron et al., "Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis", J NEUROIMM, 102(1), 2000, pp. 26-31

Abstract

Dexanabinol (HU-211) is a synthetic non-psychotropic cannabinoid which suppresses TNF-a production in the brain and peripheral blood. The effects of dexanabinol in rat experimental autoimmune encephalomyelitis (EAE) were studied using different doses, modes of administration and time regimes. Dexanabinol, 5 mg/kg i.v. given once after disease onset (day 10), significantlyreduced maximal EAE score. Increasing the dose or treatment duration resulted in further suppression of EAE. Drug administration at earlier phases during disease induction was not effective. Histological studies supported the clinical findings demonstrating reduction in the inflammatory response inthe brain and spinal cord in animals treated with dexanabinol. The resultssuggest that dexanabinol may provide an alternative mode of treatment for acute exacerbations of multiple sclerosis (MS). (C) 2000 Elsevier Science B. V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:12:30